Oct 6, 2026 7:30 am EDT SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sep 28, 2026 7:30 am EDT SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
Sep 22, 2026 8:00 am EDT SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
Sep 15, 2026 8:00 am EDT SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
Sep 10, 2026 8:00 am EDT SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
Aug 10, 2026 4:30 pm EDT SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Jun 30, 2026 8:00 am EDT SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
